Tomatoes metabolically engineered to be enriched by the antiparkinsonian drug levodopa may provide a novel, cost-effective source of the drug for patients with Parkinson disease.
Tomatoes metabolically engineered to be enriched by the antiparkinsonian drug levodopa may provide a novel, cost-effective source of the drug for patients with Parkinson disease (PD), according to study findings published in Metabolic Engineering.
In management of PD, food-drug interactions are vital to monitor, as factors such as the amount of dietary protein intake can affect the efficacy of levodopa. Moreover, levodopa is naturally produced from tyrosine, an amino acid found in walnuts and other plants, indicating its potential to be administered by natural plant sources.
Scientists from the John Innes Centre in England sought to examine whether levodopa could be synthetically engineered in tomatoes, a fleshy fruit with a complete well-characterized genome that does not normally accumulate the amino acid. Beyond examining the plausibiity of this process, they wanted to see if it may offer opportunities for new phyto-production of levodopa, which over time loses efficacy and can contribute to significant adverse events, particularly motor fluctuations and dyskinesias.
“In this study, L-DOPA-accumulating tomatoes were generated, in a fruit-specific manner, to avoid yield penalties or possible toxicity effects of levodopa on plant development,” explained the study authors. “Tomato fruit were the organ of choice, since they are relatively rich in ascorbate, which could prevent the oxidation of L-DOPA and the generation of melanin, which might, in turn, cause further oxidative stress.”
Researchers inserted a gene encoding a tyrosinase, an enzyme that uses tyrosine to build molecules such as levodopa, that worked to elevate the level of levodopa in the fruit part of the plant. This process then led to higher yields than those associated with levodopa production in the whole plant.
Notably, the levels of levodopa observed in the tomato fruit (150 mg per kg of tomatoes) were comparable to those in other levodopa-accumulating plants. This was achieved without known issues, such as toxicity, that have hindered plant metabolic production of the drug in the past.
Speaking on the potential of these findings and this specific crop, corresponding author of the study Cathie Martin, FRS, project leader, Department of Metabolic Biology, John Innes Centre, said in a statement that because tomatoes can be grown with relatively little infrastructure, production can be scaled up at relatively low cost.
“A local industry could prepare levodopa from tomatoes because it's soluble and you can do extractions. Then you could make a purified product relatively low tech which could be dispensed locally," expanded Martin.
As mentioned in the study’s accompanying press release, PD is a growing issue in developing countries where many residents may not be able to afford the price of synthetic levodopa, indicating the findings’ potential to benefit populations of lower socioeconomic status.
Reference
Breitel D, Brett P, Alseekh S, Fernie AR, Butelli E, Martin C. Metabolic engineering of tomato fruit enriched in L-DOPA. Metab Eng. Published online November 23, 2020. doi:10.1016/j.ymben.2020.11.011
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More